FDA/NIH dental MOU
This article was originally published in The Gray Sheet
Memorandum of understanding between FDA and the National Institutes of Health's National Institute of Dental Research has as its "principal goal" the reduction of time between the research and development phase of a dental product's life cycle and its commercial availability, FDA says in a June 2 Federal Register notice. The MOU will "facilitate interactions between" NIDR and the agency regarding "improvements in the quality and relevance of pre-clinical and clinical research" on products for use in oral health care. By enhancing the quality of product-related research, the organizations will "facilitate and improve premarket evaluations"...
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.